Get the RNN Research Report and
Also Receive Our Top Trades for 2017!

Rexahn Pharmaceuticals, Inc.

On May 8, 2017, Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced that it will present preliminary data from the Phase IIa study of RX-3117 in advanced and metastatic bladder cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, which is being held June 2-6 in Chicago, Illinois. (See Research Report)
Download Research Report
on RNN Now